Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Miles

Showing results (491-500 of 501) with videos related to

Pageof 51
Sort By:
Journal of Medicinal Chemistry|October 21, 2021
Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ)Guillaume Mata, Dillon H Miles, Samuel L Drew, et al.
Journal of Medicinal Chemistry|September 1, 2020
Discovery of Potent and Selective PI3Kγ InhibitorsSamuel L Drew, Rhiannon Thomas-Tran, Joel W Beatty, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A Olsen, Sean Whittaker, Youn H Kim, et al.
American Journal of Medical Genetics. Part A|March 16, 2013
Investigation of NRXN1 deletions: clinical and molecular characterizationMindy Preston Dabell, Jill A Rosenfeld, Patricia Bader, et al.
Nature Genetics|November 16, 2018
Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndromeTenzin Gayden, Fernando E Sepulveda, Dong-Anh Khuong-Quang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patientsRoberto N Miranda, Tariq N Aladily, H Miles Prince, et al.
Nature Genetics|October 31, 2018
Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndromeTenzin Gayden, Fernando E Sepulveda, Dong-Anh Khuong-Quang, et al.
Blood|July 15, 2025
A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk StratificationJulia J Scarisbrick, Pietro Quaglino, Sean J Whittaker, et al.
Pageof 51

Showing results (491-500 of 501) with videos related to

Sort By:
Pageof 51
Journal of Medicinal Chemistry|October 21, 2021
Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ)Guillaume Mata, Dillon H Miles, Samuel L Drew, et al.
Journal of Medicinal Chemistry|September 1, 2020
Discovery of Potent and Selective PI3Kγ InhibitorsSamuel L Drew, Rhiannon Thomas-Tran, Joel W Beatty, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A Olsen, Sean Whittaker, Youn H Kim, et al.
American Journal of Medical Genetics. Part A|March 16, 2013
Investigation of NRXN1 deletions: clinical and molecular characterizationMindy Preston Dabell, Jill A Rosenfeld, Patricia Bader, et al.
Nature Genetics|November 16, 2018
Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndromeTenzin Gayden, Fernando E Sepulveda, Dong-Anh Khuong-Quang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patientsRoberto N Miranda, Tariq N Aladily, H Miles Prince, et al.
Nature Genetics|October 31, 2018
Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndromeTenzin Gayden, Fernando E Sepulveda, Dong-Anh Khuong-Quang, et al.
Blood|July 15, 2025
A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk StratificationJulia J Scarisbrick, Pietro Quaglino, Sean J Whittaker, et al.
Pageof 51